EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs

Wolfgang A Weber, Johannes Czernin, Michael E Phelps, Harvey R Herschman

Nature Clinical Practice Oncology · 2008-01 · 5 (1) · 44-54

DOI: 10.1038/ncponc0982 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Clinical Practice Oncology, 2008-01. Verfasst von Wolfgang A Weber und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, University of Freiberg, Germany. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Positron-Emission Tomography. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted drugs hold great promise for the treatment of malignant tumors; however, there are several challenges for efficient evaluation of these drugs in preclinical and clinical studies. These challenges include identifying the 'correct', biologically active concentration and dose schedule, selecting the patients likely to benefit from treatment, monitoring inhibition of the target protein or pathway, and assessing the response of the tumor to therapy. Although anatomic imaging will remain important, molecular imaging provides several new opportunities to make the process of drug development more efficient. Various techniques for molecular imaging that enable noninvasive and quantitative imaging are now available in the preclinical and clinical settings, to aid development and evaluation of new drugs for the treatment of cancer. In this Review, we discuss the integration of molecular imaging into the process of drug development and how molecular imaging can address key questions in the preclinical and clinical evaluation of new targeted drugs. Examples include imaging of the expression and inhibition of drug targets, noninvasive tissue pharmacokinetics, and early assessment of the tumor response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingPositron-Emission TomographyAnimalsAntineoplastic AgentsBinding, CompetitiveClinical Trials as TopicDose-Response Relationship, DrugDrug Delivery SystemsDrug DesignDrug Screening Assays, AntitumorHumansImmunoconjugatesNanoparticlesNeoplasm ProteinsNeoplasmsPatient SelectionRadiopharmaceuticalsSignal TransductionTissue Distribution

Substanzen

Antineoplastic AgentsImmunoconjugatesNeoplasm ProteinsRadiopharmaceuticals

Autor:innen und Institutionen

  • Nuclear Medicine, University of Freiberg, Germany.

Förderung

  • NCI NIH HHS

Zitieren

APA

Weber, W. A., Czernin, J., Phelps, M. E., & Herschman, H. R. (2008). Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nature Clinical Practice Oncology, 5(1), 44-54. https://doi.org/10.1038/ncponc0982

Vancouver

Weber WA, Czernin J, Phelps ME, Herschman HR. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nature Clinical Practice Oncology. 2008;5(1):44-54. doi:10.1038/ncponc0982

BibTeX
@article{Weber2008,
  author = {Weber, Wolfgang A and Czernin, Johannes and Phelps, Michael E and Herschman, Harvey R},
  title = {Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs},
  journal = {Nature Clinical Practice Oncology},
  year = {2008},
  volume = {5},
  number = {1},
  pages = {44--54},
  doi = {10.1038/ncponc0982}
}
Kostenlos starten →